L200s

N/A

Report date: 2023/04/23 14:37:52

Base Information

Drug NameL200s
Drug Alias NameL200sL-200-s
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsNasopharyngeal NeoplasmsLymphoma, Extranodal NK-T-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTcrcure Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsNasopharyngeal NeoplasmsLymphoma, Extranodal NK-T-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A